These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27657518)

  • 1. American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions.
    Larenas-Linnemann DE; Hauswirth DW; Calabria CW; Sher LD; Rank MA
    Allergy Asthma Proc; 2016 Sep; 37(5):112-22. PubMed ID: 27657518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Academy of Asthma, Allergy & Immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children.
    Calabria CW; Hauswirth DW; Rank M; Sher L; Larenas-Linnemann D
    Allergy Asthma Proc; 2017 Mar; 38(2):121-129. PubMed ID: 28234049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy.
    Bernstein DI; Epstein TEG
    Allergy Asthma Proc; 2020 Mar; 41(2):108-111. PubMed ID: 32122446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013).
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    Ann Allergy Asthma Immunol; 2016 Apr; 116(4):354-359.e2. PubMed ID: 26948485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma.
    Epstein TG; Murphy-Berendts K; Liss GM; Bernstein DI
    Ann Allergy Asthma Immunol; 2021 Jul; 127(1):64-69.e1. PubMed ID: 33753219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.
    Calderón MA; Vidal C; Rodríguez Del Río P; Just J; Pfaar O; Tabar AI; Sánchez-Machín I; Bubel P; Borja J; Eberle P; Reiber R; Bouvier M; Lepelliez A; Klimek L; Demoly P;
    Allergy; 2017 Mar; 72(3):462-472. PubMed ID: 27718250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey on immunotherapy practice patterns: dose, dose adjustments, and duration.
    Larenas-Linnemann DE; Gupta P; Mithani S; Ponda P
    Ann Allergy Asthma Immunol; 2012 May; 108(5):373-378.e3. PubMed ID: 22541411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions.
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    J Allergy Clin Immunol Pract; 2014; 2(2):161-7. PubMed ID: 24607043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation].
    Kleine-Tebbe J; Ackermann-Simon J; Hanf G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):343-50. PubMed ID: 22373847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose Adjustment After Gaps in Administration of Subcutaneous Immunotherapy From a Past Survey: Work Group Report of the AAAAI Allergen Standardization and Allergy Diagnostics Committee.
    Larenas-Linnemann D; Ponda P; Creticos P; Bernstein D; Epstein T; Williams P
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):145-148.e4. PubMed ID: 36443172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicians' experience and opinion on contraindications to allergen immunotherapy: The CONSIT survey.
    Rodríguez Del Rio P; Pitsios C; Tsoumani M; Pfaar O; Paraskevopoulos G; Gawlik R; Valovirta E; Larenas-Linnemann D; Demoly P; Calderón MA
    Ann Allergy Asthma Immunol; 2017 May; 118(5):621-628.e1. PubMed ID: 28477792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions?
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    Ann Allergy Asthma Immunol; 2013 Apr; 110(4):274-8, 278.e1. PubMed ID: 23535092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergen immunotherapy for respiratory allergy: to what extent can the risk of systemic reactions be reduced?
    Incorvaia C; Pucciarini F; Makri E; Gritti BL; Ridolo E
    Expert Opin Drug Saf; 2020 Jul; 19(7):843-848. PubMed ID: 32511028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
    Sánchez-Borges M; Bernstein DI; Calabria C
    Immunol Allergy Clin North Am; 2020 Feb; 40(1):25-39. PubMed ID: 31761119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors.
    Epstein TG; Liss GM; Berendts KM; Bernstein DI
    J Allergy Clin Immunol Pract; 2019; 7(6):1996-2003.e1. PubMed ID: 30776526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perception and practice of sublingual immunotherapy among practicing allergists.
    Tucker MH; Tankersley MS;
    Ann Allergy Asthma Immunol; 2008 Oct; 101(4):419-25. PubMed ID: 18939732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology.
    CMAJ; 1995 May; 152(9):1413-9. PubMed ID: 7728690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
    Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.